Del 44 i serien Topics in Medicinal Chemistry

Advances in Drug Discovery for Alzheimer’s Disease

Inbunden, Engelska, 2026

2 489 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

This book reviews recent advances in drug discovery for Alzheimer’s disease, focusing on major targets and approaches. Topics include approaches to targeting—directly or indirectly—the two proteins that pathologically accumulate in the brain in Alzheimer’s disease, the amyloid β-peptide and the microtubule-associated protein tau, which remain top targets for disease prevention and treatment. A chapter on the emerging area of AI approaches to drug repurposing and discovery will also be included, with examples of the use of big data to identify novel therapeutic modalities. An overview chapter will put these approaches into broader context; describe other important and emerging approaches, targets, and drug candidates; and provide a critical assessment of the potential of these approaches to lead to effective therapeutics. This book is particularly appealing to researchers, clinicians, and students in the fields of medicinal chemistry, neuroscience, pharmacology, and biomedical sciences, as well as anyone interested in the latest advancements in Alzheimer’s disease research and drug discovery.

Produktinformation

Utgivningsdatum2026-07-01
Mått155 x 235 x 21 mm
Vikt580 g
FormatInbunden
SpråkEngelska
SerieTopics in Medicinal Chemistry
Antal sidor266
FörlagSpringer Nature Switzerland AG
ISBN9783032287298

Tillhör följande kategorier

Kemi inom Naturvetenskap och teknik
Fysikalisk kemi inom Naturvetenskap och teknik
Biovetenskap inom Naturvetenskap och teknik
Alzheimer, demens inom Medicin

Michael Wolfe is the Mathias P. Mertes Professor of Medicinal Chemistry at the University of Kansas, USA, where he has worked since 2016. He began his academic career at the University of Tennessee in Memphis in 1994, before moving to Harvard Medical School and Brigham and Women’s Hospital in 1999. He was appointed Professor of Neurology in 2008. His research career has been dedicated elucidating the molecular basis of Alzheimer’s and related disorders and identifying effective pharmacological interventions. Awards for his work include the MetLife Award for Biomedical Research (2008), a Zenith Fellows Award from the Alzheimer’s Association (2008), and the Potamkin Prize from the American Academy of Neurology (2009).

Drug Discovery for Alzheimer's Disease: Current Status.- Recent Advances in the Development of γ-Secretase Modulators to Treat Alzheimer’s Disease.- Beta-Secretase Inhibitors.- Tau Aggregation Inhibitors.- The Role of Molecular Chaperones in Tau Proteostasis: Potential Therapeutic Opportunities in Tauopathies.- Targeting Caspase-2 for the Treatment of Dementia.- The Role of Artificial Intelligence for Drug Repurposing in Alzheimer’s Disease.